DR10624 not checked

Zhejiang Doer Biologics Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Novel investigational biologic agent for severe hypertriglyceridemia, administered via weekly subcutaneous injection with two titrated dose regimens (low-dose and high-dose) for 64 weeks double-blind treatment period.”In the company’s words, NCT07693777 on ClinicalTrials.gov
Tested for
Hypertriglyceridemia (2 trials), Severe Hypertriglyceridemia (sHTG), Severe Hypertriglyceridemia, MASLD
Main trialPhase 3
“This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG). Eligible participants have persistently elevated fasting triglycerides despite stable background lipid-lowering therapy. Subjects will be randomized at a 2:2:1 ratio to three treatment arms: DR10624 low dose, DR10624 high dose, or matching placebo, receiving weekly subcutaneous injections for a total of 64 weeks double-blind treatment, followed by a 4-week post-treatment…”In the company’s words, NCT07693777 on ClinicalTrials.gov

Other drugs for Hypertriglyceridemia

All 15 drugs for Hypertriglyceridemia

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 14 Feb 2029 A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Phase 3Not yet recruiting Jun 2030 A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
Phase 2Active, not recruiting 18 Jun 2026 Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
Phase 2Not yet recruiting Apr 2028 A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
Phase 2Completed 30 Jun 2025 A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Phase 1Completed 10 Oct 2024 A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow DR10624

Following is part of Solo: you see every change to DR10624 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in